{"count": 2, "results": [{"_id": "34745769", "pmid": 34745769, "pmcid": "PMC8565822", "title": "Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner", "journal": "Oncoimmunology", "authors": ["Xia W", "Qi X", "Li M", "Wu Y", "Sun L", "Fan X", "Yuan Y", "Li J"], "date": "2021-10-29T00:00:00Z", "doi": "10.1080/2162402X.2021.1995999", "meta_date_publication": "2021", "meta_volume": "10", "meta_issue": "1", "meta_pages": "1995999", "score": 50251.703, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ enhances the cytolytic activity of @<m>DISEASE_Ascites</m> @DISEASE_MESH:D001201 @@@ascites@@@ NK cells from @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@cancer@@@ @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Xia W, Qi X, Li M, Wu Y, Sun L, Fan X, Yuan Y, Li J. Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner Oncoimmunology. 2021;10(1):1995999. PMID: 34745769", "BibTeX": "@article{34745769, title={Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner}, author={Xia W and Qi X and Li M and Wu Y and Sun L and Fan X and Yuan Y and Li J}, journal={Oncoimmunology}, volume={10}, number={1}, pages={1995999}}"}}, {"_id": "40937057", "pmid": 40937057, "title": "Impact of overt and subclinical hepatogenous diabetes and metformin treatment on circulatory function, renal function and hemodynamics, inflammatory activity, and prognosis in patients with cirrhosis and ascites.", "journal": "Ann Gastroenterol", "authors": ["Tsiakas I", "Kosmidou M", "Despotis G", "Biros D", "Tsiouris S", "Xourgia X", "Lakkas L", "Markopoulos GS", "Bairaktari E", "Kolios G", "Milionis H", "Kalambokis G"], "date": "2025-09-01T00:00:00Z", "doi": "10.20524/aog.2025.0990", "meta_date_publication": "2025 Sep-Oct", "meta_volume": "38", "meta_issue": "5", "meta_pages": "545-553", "score": 50251.04, "text_hl": "Impact of overt and subclinical @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@hepatogenous diabetes@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment on circulatory function, renal function and hemodynamics, @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ activity, and prognosis in @SPECIES_9606 @@@patients@@@ with @DISEASE_Fibrosis @DISEASE_MESH:D005355 @@@cirrhosis@@@ and @<m>DISEASE_Ascites</m> @DISEASE_MESH:D001201 @@@ascites@@@.", "citations": {"NLM": "Tsiakas I, Kosmidou M, Despotis G, Biros D, Tsiouris S, Xourgia X, Lakkas L, Markopoulos GS, Bairaktari E, Kolios G, Milionis H, Kalambokis G. Impact of overt and subclinical hepatogenous diabetes and metformin treatment on circulatory function, renal function and hemodynamics, inflammatory activity, and prognosis in patients with cirrhosis and ascites. Ann Gastroenterol. 2025 Sep-Oct;38(5):545-553. PMID: 40937057", "BibTeX": "@article{40937057, title={Impact of overt and subclinical hepatogenous diabetes and metformin treatment on circulatory function, renal function and hemodynamics, inflammatory activity, and prognosis in patients with cirrhosis and ascites.}, author={Tsiakas I and Kosmidou M and Despotis G and Biros D and Tsiouris S and Xourgia X and Lakkas L and Markopoulos GS and Bairaktari E and Kolios G and Milionis H and Kalambokis G}, journal={Ann Gastroenterol}, volume={38}, number={5}, pages={545-553}}"}}]}